CD47 and acute myeloid leukemia: Finally, the anti-CD47 monoclonal antibody CC-90002 was tested in a Phase I study of patients with R/R AML; however, the agent was poorly tolerated, no objective responses were observed, and the development of anti-drug antibodies was noted at all dose levels (Zeidan et al., 2019a).